Insulet Corporation
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a PODD research report →
About the company
Insulet Corporation specializes in the creation, production, and distribution of advanced insulin management systems for individuals living with insulin-dependent diabetes. At the core of their offerings is the Omnipod System, an innovative solution featuring a unique, self-adhesive, and disposable Omnipod device. This tubeless unit can be directly applied to the body for a duration of up to three days, and it operates in conjunction with a wireless handheld personal diabetes manager.
- CEO
- Ashley A. McEvoy
- IPO
- 2007
- Employees
- 5,400
- HQ
- Acton, MA, US
Price Chart
- Market Cap
- $10.27B
- P/E
- 34.28
- P/S
- 3.54
- P/B
- 7.97
- EV/EBITDA
- 18.68
- Div Yield
- 0.00%
- Gross Margin
- 71.01%
- Op Margin
- 17.48%
- Net Margin
- 10.44%
- ROE
- 21.38%
- ROIC
- 16.39%
- Revenue
- $2.71B · 30.73%
- Net Income
- $247.10M · -40.93%
- EPS
- $3.51 · -41.21%
- Op Income
- $473.80M
- FCF YoY
- 23.67%
- 52W High
- $354.88
- 52W Low
- $140.63
- 50D MA
- $169.67
- 200D MA
- $260.28
- Beta
- 1.13
- Avg Volume
- 1.33M
Get TickerSpark's AI analysis on PODD
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 3, 26 | STONESIFER TIMOTHY C. | buy | 2,790 |
| Jun 3, 26 | BORIO LUCIANA | sell | 418 |
| May 20, 26 | WEATHERMAN ELIZABETH H | other | 1,660 |
| May 20, 26 | STONESIFER TIMOTHY C. | other | 1,660 |
| May 20, 26 | Scannell Timothy J | other | 1,660 |
| May 20, 26 | MINOGUE MICHAEL R | other | 1,660 |
| May 20, 26 | Huffines Robert Luther | other | 1,660 |
| May 20, 26 | Hopfield Jessica | other | 1,660 |
| May 20, 26 | Frederick Wayne A.I. | other | 1,660 |
| May 20, 26 | BORIO LUCIANA | other | 1,660 |
Our PODD coverage
Recent articles, reports, and earnings notes.
Insulet (PODD): Growth Runway Still Justifies a Buy
Insulet is compounding revenue, margins, and free cash flow while expanding Omnipod’s reach in type 1 and type 2 diabetes. The stock still trades at a premium, but the growth runway and product leadership remain compelling.
Insulet Corporation (PODD) drops after deep earnings analysis
Insulet beat on EPS and revenue, lifted full-year guidance, and still saw PODD drop sharply. This deep-dive looks beyond the headline beat to examine Omnipod growth, margin expansion, guidance nuance, and why investors focused on valuation and reaction rather than the strong quarter.
Insulet Corporation (PODD) drops after earnings beats
Insulet Corporation (PODD) drops 6.3% even after earnings beats, as investors react to the latest quarterly results and outlook.
Want a deeper read on PODD?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
Similar companies
Peers in the same neighborhood.